Publications 2024

Skotheim RI, Bogaard M, Carm KT, Axcrona U, Axcrona K (2024)
Prostate cancer: Molecular aspects, consequences, and opportunities of the multifocal nature
Biochim Biophys Acta Rev Cancer, 1879 (2), 189080
DOI 10.1016/j.bbcan.2024.189080, PubMed 38272101

Publications 2023

Bogaard M, Skotheim RI, Maltau AV, Kidd SG, Lothe RA, Axcrona K, Axcrona U (2023)
'High proliferative cribriform prostate cancer' defines a patient subgroup with an inferior prognosis
Histopathology, 83 (6), 853-869
DOI 10.1111/his.15012, PubMed 37501635

Switlyk MD, Hopland A, Reitan E, Sivanesan S, Brennhovd B, Axcrona U, Hole KH (2023)
Multiparametric Magnetic Resonance Imaging of Penile Cancer: A Pictorial Review
Cancers (Basel), 15 (22)
DOI 10.3390/cancers15225324, PubMed 38001583

Switlyk MD, Hopland A, Sivanesan S, Brennhovd B, Ottosson F, Berner K, Axcrona U, Hole KH (2023)
Multi-parametric MRI without artificial erection for preoperative assessment of primary penile carcinoma: A pilot study on the correlation between imaging and histopathological findings
Eur J Radiol Open, 10, 100478
DOI 10.1016/j.ejro.2023.100478, PubMed 36793771

Publications 2022

Axcrona K, Aas K, Axcrona U, Skotheim RI (2022)
Re: Spatially Resolved Clonal Copy Number Alterations in Benign and Malignant Tissue
Eur Urol, 83 (2), 183
DOI 10.1016/j.eururo.2022.11.013, PubMed 36464529

Carm KT, Johannessen B, Bogaard M, Bakken AC, Maltau AV, Hoff AM, Axcrona U, Axcrona K, Lothe RA, Skotheim RI (2022)
Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer
Int J Cancer, 152 (5), 945-951
DOI 10.1002/ijc.34226, PubMed 35880692

Fontugne J, Cai PY, Alnajar H, Bhinder B, Park K, Ye H, Beg S, Sailer V, Siddiqui J, Blattner-Johnson M, Croyle JA, Noorzad Z, Calagua C, MacDonald TY, Axcrona U, Bogaard M, Axcrona K, Scherr DS, Sanda MG, Johannessen B, Chinnaiyan AM, Elemento O, Skotheim RI, Rubin MA, Barbieri CE et al. (2022)
Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci
JCI Insight, 7 (4)
DOI 10.1172/jci.insight.155309, PubMed 35050902

Hugosson J, Månsson M, Wallström J, Axcrona U, Carlsson SV, Egevad L, Geterud K, Khatami A, Kohestani K, Pihl CG, Socratous A, Stranne J, Godtman RA, Hellström M, GÖTEBORG-2 Trial Investigators (2022)
Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only
N Engl J Med, 387 (23), 2126-2137
DOI 10.1056/NEJMoa2209454, PubMed 36477032

Kidd SG, Bogaard M, Carm KT, Bakken AC, Maltau AMV, Løvf M, Lothe RA, Axcrona K, Axcrona U, Skotheim RI (2022)
In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis
Mol Oncol, 16 (15), 2810-2822
DOI 10.1002/1878-0261.13225, PubMed 35574900

Skotheim RI, Axcrona U, Axcrona K (2022)
Re: Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer
Eur Urol, 81 (4), 431
DOI 10.1016/j.eururo.2021.12.031, PubMed 35031159

Strømme JM, Johannessen B, Kidd SG, Bogaard M, Carm KT, Zhang X, Sveen A, Mathelier A, Lothe RA, Axcrona U, Axcrona K, Skotheim RI (2022)
Expressed prognostic biomarkers for primary prostate cancer independent of multifocality and transcriptome heterogeneity
Cancer Gene Ther, 29 (8-9), 1276-1284
DOI 10.1038/s41417-022-00444-7, PubMed 35194199

Publications 2021

Kidd SG, Carm KT, Bogaard M, Olsen LG, Bakken AC, Løvf M, Lothe RA, Axcrona K, Axcrona U, Skotheim RI (2021)
High expression of SCHLAP1 in primary prostate cancer is an independent predictor of biochemical recurrence, despite substantial heterogeneity
Neoplasia, 23 (6), 634-641
DOI 10.1016/j.neo.2021.05.012, PubMed 34107378

Tryggestad AMA, Axcrona K, Axcrona U, Bigalke I, Brennhovd B, Inderberg EM, Hønnåshagen TK, Skoge LJ, Solum G, Saebøe-Larssen S, Josefsen D, Olaussen RW, Aamdal S, Skotheim RI, Myklebust TÅ, Schendel DJ, Lilleby W, Dueland S, Kvalheim G (2021)
Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy
Prostate, 82 (2), 245-253
DOI 10.1002/pros.24267, PubMed 34762317

Publications 2020

Arstad C, Taskén K, Refinetti P, Axcrona U, Giercksky KE, Ekstrøm PO (2020)
Somatic Mitochondrial DNA Point Mutations Used as Biomarkers to Demonstrate Genomic Heterogeneity in Primary Prostate Cancer
Prostate Cancer, 2020, 7673684
DOI 10.1155/2020/7673684, PubMed 32908706

Saeednejad Zanjani L, Madjd Z, Axcrona U, Abolhasani M, Rasti A, Asgari M, Fodstad Ø, Andersson Y (2020)
Cytoplasmic expression of B7-H3 and membranous EpCAM expression are associated with higher grade and survival outcomes in patients with clear cell renal cell carcinoma
Ann Diagn Pathol, 46, 151483
DOI 10.1016/j.anndiagpath.2020.151483, PubMed 32143173

Publications 2019

Carm KT, Hoff AM, Bakken AC, Axcrona U, Axcrona K, Lothe RA, Skotheim RI, Løvf M (2019)
Interfocal heterogeneity challenges the clinical usefulness of molecular classification of primary prostate cancer
Sci Rep, 9 (1), 13579
DOI 10.1038/s41598-019-49964-7, PubMed 31537872

Publications 2018

Lønning PE, Berge EO, Bjørnslett M, Minsaas L, Chrisanthar R, Høberg-Vetti H, Dulary C, Busato F, Bjørneklett S, Eriksen C, Kopperud R, Axcrona U, Davidson B, Bjørge L, Evans G, Howell A, Salvesen HB, Janszky I, Hveem K, Romundstad PR, Vatten LJ, Tost J, Dørum A, Knappskog S (2018)
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk
Ann Intern Med, 168 (5), 326-334
DOI 10.7326/M17-0101, PubMed 29335712

Løvf M, Zhao S, Axcrona U, Johannessen B, Bakken AC, Carm KT, Hoff AM, Myklebost O, Meza-Zepeda LA, Lie AK, Axcrona K, Lothe RA, Skotheim RI (2018)
Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity
Eur Urol, 75 (3), 498-505
DOI 10.1016/j.eururo.2018.08.009, PubMed 30181068

Publications 2017

Beisland C, Johannesen TB, Klepp O, Axcrona U, Torgersen KM, Kowalski J, Solli O, Sandin R, Oldenburg J (2017)
Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study
Onco Targets Ther, 10, 371-385
DOI 10.2147/OTT.S123061, PubMed 28144152

Saeter T, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2017)
Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population-Based Study
Prostate, 77 (8), 859-865
DOI 10.1002/pros.23326, PubMed 28240424

Aas K, Axcrona K, Kvåle R, Møller B, Myklebust TÅ, Axcrona U, Berge V, Fosså SD (2017)
Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway
Urology, 110, 140-147
DOI 10.1016/j.urology.2017.07.048, PubMed 28823634

Publications 2016

Saeter T, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2016)
Combining lymphovascular invasion with reactive stromal grade predicts prostate cancer mortality
Prostate, 76 (12), 1088-94
DOI 10.1002/pros.23192, PubMed 27271973

Publications 2015

Brabrand S, Johannessen B, Axcrona U, Kraggerud SM, Berg KG, Bakken AC, Bruun J, Fosså SD, Lothe RA, Lehne G, Skotheim RI (2015)
Exome sequencing of bilateral testicular germ cell tumors suggests independent development lineages
Neoplasia, 17 (2), 167-74
DOI 10.1016/j.neo.2014.12.005, PubMed 25748235

Saeter T, Bogaard M, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2015)
The relationship between perineural invasion, tumor grade, reactive stroma and prostate cancer-specific mortality: A clinicopathologic study on a population-based cohort
Prostate, 76 (2), 207-14
DOI 10.1002/pros.23112, PubMed 26477789

Saeter T, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2015)
The prognostic value of reactive stroma on prostate needle biopsy: a population-based study
Prostate, 75 (6), 662-71
DOI 10.1002/pros.22957, PubMed 25620661

Publications 2014

Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A et al. (2014)
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study
Eur Urol, 66 (3), 489-99
DOI 10.1016/j.eururo.2014.01.003, PubMed 24484606

Servoll E, Vlatkovic L, Sæter T, Nesland JM, Axcrona U, Waaler G, Axcrona K (2014)
The length of a positive surgical margin is of prognostic significance in patients with clinically localized prostate cancer treated with radical prostatectomy
Urol Int, 93 (3), 289-95
DOI 10.1159/000362342, PubMed 25170745

Publications 2013

Liu Y, Sæter T, Vlatkovic L, Servoll E, Waaler G, Axcrona U, Giercksky KE, Nesland JM, Suo ZH, Axcrona K (2013)
Dendritic and lymphocytic cell infiltration in prostate carcinoma
Histol Histopathol, 28 (12), 1621-8
DOI 10.14670/HH-28.1621, PubMed 23729368

Liu Y, Wu X, Li X, Kvalheim G, Axcrona U, Axcrona K, Suo Z (2013)
Blocking mtDNA replication upregulates the expression of stemness-related genes in prostate cancer cell lines
Ultrastruct Pathol, 37 (4), 258-66
DOI 10.3109/01913123.2013.770112, PubMed 23634795

Ma Y, Liang D, Liu J, Wen JG, Servoll E, Waaler G, Sæter T, Axcrona K, Vlatkovic L, Axcrona U, Paus E, Yang Y, Zhang Z, Kvalheim G, Nesland JM, Suo Z (2013)
SHBG is an important factor in stemness induction of cells by DHT in vitro and associated with poor clinical features of prostate carcinomas
PLoS One, 8 (7), e70558 (Retracted)
DOI 10.1371/journal.pone.0070558, PubMed 23936228

Publications 2012

Brabrand S, Fosså SD, Cvancarova M, Axcrona U, Lehne G (2012)
Probability of metachronous testicular cancer in patients with biopsy-proven intratubular germ cell neoplasia depends on first-time treatment of germ cell cancer
J Clin Oncol, 30 (32), 4004-10
DOI 10.1200/JCO.2011.40.8914, PubMed 23071246

Publications 2007

Park D, Kåresen R, Axcrona U, Noren T, Sauer T (2007)
Expression pattern of adhesion molecules (E-cadherin, alpha-, beta-, gamma-catenin and claudin-7), their influence on survival in primary breast carcinoma, and their corresponding axillary lymph node metastasis
APMIS, 115 (1), 52-65
DOI 10.1111/j.1600-0463.2007.apm_524.x, PubMed 17223851